Extension Study up to 3 Years for Secukinumab in Psoriatic Arthritis
Public ClinicalTrials.gov record NCT01892436. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Three-year Extension Study to Evaluate the Long Term Efficacy, Safety and Tolerability of Secukinumab in Patients With Active Psoriatic Arthritis
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study was designed as a 3-year extension to the phase III core study CAIN457F2306. It aimed to provide continuous treatment with secukinumab in pre-filled syringes (PFS) for subjects who completed the core study CAIN457F2306, to obtain further long term efficacy, safety and tolerability information in subjects with active psoriatic arthritis receiving secukinumab every 4 weeks. At Week 104 of the study CAIN457F2306, eligible subjects completed the assessments associated with the core study visit and subsequently continued in this extension study on the same dose that they were receiving during the core study. The regular assessments of disease activity ensure that subjects who are experienced worsening of disease in any of the treatment groups could exit the study upon their own wish or based on the advice of the investigator at any time.
Study identification
- NCT ID
- NCT01892436
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 460 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 30, 2013 (Actual)
- Primary completion
- Jan 11, 2018 (Actual)
- Completion
- Jan 11, 2018 (Actual)
- Last update posted
- Jun 12, 2019
2013 – 2018
United States locations
- U.S. sites
- 22
- U.S. states
- 15
- U.S. cities
- 21
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Novartis Investigative Site | Anniston | Alabama | 36207-5710 | — |
| Novartis Investigative Site | Mesa | Arizona | 85202 | — |
| Novartis Investigative Site | Paradise Valley | Arizona | 85253 | — |
| Novartis Investigative Site | Upland | California | 91786 | — |
| Novartis Investigative Site | Tamarac | Florida | 33321 | — |
| Novartis Investigative Site | Eagan | Minnesota | 55121 | — |
| Novartis Investigative Site | St Louis | Missouri | 63117 | — |
| Novartis Investigative Site | Lincoln | Nebraska | 68516 | — |
| Novartis Investigative Site | Freehold | New Jersey | 07728 | — |
| Novartis Investigative Site | Charlotte | North Carolina | 28210 | — |
| Novartis Investigative Site | Oklahoma City | Oklahoma | 73103 | — |
| Novartis Investigative Site | Duncansville | Pennsylvania | 16635 | — |
| Novartis Investigative Site | Charleston | South Carolina | 29460 | — |
| Novartis Investigative Site | Columbia | South Carolina | 29204 | — |
| Novartis Investigative Site | Jackson | Tennessee | 38305 | — |
| Novartis Investigative Site | Benbrook | Texas | 76126 | — |
| Novartis Investigative Site | Dallas | Texas | 75216 | — |
| Novartis Investigative Site | Dallas | Texas | 75246 | — |
| Novartis Investigative Site | Houston | Texas | 77074 | — |
| Novartis Investigative Site | League City | Texas | 77573 | — |
| Novartis Investigative Site | Mesquite | Texas | 75150 | — |
| Novartis Investigative Site | Seattle | Washington | 98122 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 72 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01892436, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 12, 2019 · Synced Oct 17, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT01892436 live on ClinicalTrials.gov.